Testing for superiority or inferiority after concluding equivalence?

被引:3
作者
Chuang-Stein, C [1 ]
机构
[1] Pharmacia Corp, Clin Biostat 1, Kalamazoo, MI 49001 USA
来源
DRUG INFORMATION JOURNAL | 2001年 / 35卷 / 01期
关键词
confidence interval; equivalence; noninferiority; superiority;
D O I
10.1177/009286150103500115
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In this paper we examine the issue of testing for superiority or inferiority following the equivalence conclusion. We contrast this situation with that of testing for superiority after a noninferiority conclusion. We point out the fact that further testing is irrelevant in situations where the equivalence definition renders the inferred true treatment effect difference nonsignificant from the clinical perspective. Consequently superiority in the presence of an accompanying equivalence definition has a meaning that is different from its traditional interpretation.
引用
收藏
页码:141 / 143
页数:3
相关论文
共 5 条
[1]  
*COMM PROP MED PRO, 1999, POINTS CONS BIOST IS
[2]  
Dunnett CW, 1996, STAT MED, V15, P1729
[3]  
Hauck WW, 1999, DRUG INF J, V33, P109, DOI 10.1177/009286159903300114
[4]  
MAKUCH R, 1978, CANCER TREAT REP, V62, P1037
[5]  
Morikawa T, 1995, J Biopharm Stat, V5, P297, DOI 10.1080/10543409508835115